Navigation Links
Positive Final Data from HyCAMP Phase II Trial in Metastatic,Colorectal

BRISBANE, Australia, May 29, 2007 /PRNewswire/ -- Phase II results exceed expectations - Alchemia prepares for FDA talks on HyCAMP(TM)

Australian drug development company Alchemia Limited will commence discussions with the US Food and Drug Administration (FDA) following the successful conclusion of the Phase II clinical trial of its metastatic colorectal cancer treatment, HyCAMP(TM).

The final data from the randomized Phase II clinical trial in 80 patients with metastatic colorectal cancer treated with HyCAMP(TM) versus Camptosar(R) shows:


    - HyCAMP(TM) exerted superior anti-cancer activity with a significantly

      greater number of patients with observed tumour responses


    - A statistically significant increase in 'time to treatment failure'

      demonstrating that HyCAMP(TM) patients were able to stay on treatment

      longer due to reduced toxicity and increased efficacy


    - A significantly longer period (+116%) of 'progression-free survival' for

      patients receiving HyCAMP(TM)*


    - Patients on HyCAMP(TM) were able to receive therapy for a median of

      three times longer than those receiving Camptosar(R)*


    - A clinically significant trend towards longer overall survival for

      patients receiving HyCAMP(TM)


    - HyCAMP(TM) patients received less doses of anti-diarrheal medication

      than Camptosar(R) patients


    - This data was announced to the ASX on April 26 2007

Alchemia Chief Executive Officer, Dr Peter Smith said, "The fact that we are seeing statistically significant improvements in efficacy end-points from such a small study is a reflection of the substantial increase in anti-tumour activity seen with HyCAMP(TM). Generally, much larger studies would be required to show such effects. This data is an exceptional validation of our HyACT(TM) drug delivery technology platform and its application to the treatment of cancer
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Positive Final Data from HyCAMP Phase Trial Metastatic Colorectal
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Congressional Leaders to Introduce Legislation , WASHINGTON , ... Congressional Network (ACPCN) will join congressional leaders tomorrow to ... Savings Act." The bill by U.S. Rep. G.K. ... management (PBM) companies for medications. , "Congress is prepared ...
... AMD LASERS, the world leader in comprehensive and affordable ... Waclawik as Chief Operating Officer. In this newly created ... operations, procurement, production, quality assurance, and general financial oversight ... effort on the next-generation of product development in order ...
Cached Medicine Technology:Pharmacists Work with Congress to Address PBM Abuses 2AMD LASERS Announces the Addition of Bart Waclawik, New Chief Operating Officer 2
(Date:4/23/2014)... internal surface area of the gastro-intestinal tract has long ... meters. Scientists at the Sahlgrenska Academy have used refined ... "Actually, the inner surface of the gastro-intestinal tract is ... scientist Lars Fndriks. , The digestive tract, which passes ... the intestines, has a length of about 5 meters ...
(Date:4/23/2014)... benefits of probiotics, antioxidants and other nutritional compounds, more ... industry is getting in on the action. But legitimate ... the industry is responding with clinical research to shore ... Chemical & Engineering News (C&EN), the weekly ... M. Bomgardner, a senior editor at C&EN, writes that ...
(Date:4/23/2014)... Parents and physicians concerned about an increase in ... can breathe a sigh of relief. According to a ... years worth of data from states with and without ... to increased use among adolescents. The study is published ... of Adolescent Health . , "Any time a ...
(Date:4/23/2014)... the bottom of Alzheimer,s disease has been a ... controversies. In the latest crook in the research ... the interaction between proteins associated with the disease. ... ACS Chemical Neuroscience , could have important implications ... Krzysztof Nieznanski and colleagues explain that for years, ...
(Date:4/22/2014)... provide primary care for low-income patients may ease ... companies while improving patient health, researchers have concluded. ... health clinics that avoid costs associated with insurance ... hospital admission rates and emergency room visits, according ... Altoona. , The researchers estimated that the ...
Breaking Medicine News(10 mins):Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2
... HealthDay Reporter , TUESDAY, Feb. 1 (HealthDay News) ... from meningococcal meningitis, a potentially deadly infection of the ... up-to-date whooping cough vaccines in light of recent outbreaks, ... American Academy of Pediatrics issues updated vaccination guidelines annually. ...
... Society for Therapeutic Radiology and Oncology (ESTRO), the European ... for Medical Oncology (ESMO) in collaboration with other European ... on the 3rd International Conference on innovative approaches In ... on multidisciplinarity and innovation, this meeting will specifically cover ...
... Hospitals Case Medical Center and Case Western Reserve University ... addressing the lack of knowledge about causes and risk ... five-year study is funded by the National Cancer Institute ... Ovarian cancer, though relatively rare, is the most lethal ...
... for breast cancer delivers consistent rates of cancer detection and ... published online and in the April print edition of ... mammography at identifying suspicious areas of the breast, it is ... which can result in additional testing and false-positive results that ...
... charities and health organizations must tread carefully when ... risk compromise health promotion goals, states an editorial ... Journal ) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj110085.pdf . ... for health charities and organizations because they bring ...
... HealthDay Reporter , MONDAY, Jan. 31 (HealthDay News) ... stroke, they appear to have better odds of surviving one ... might seem odd since conventional wisdom says black patients typically ... in general. However, the same trend has been noticed in ...
Cached Medicine News:Health News:Pediatricians Issue New Vaccination Recommendations 2Health News:Pediatricians Issue New Vaccination Recommendations 3Health News:3rd international conference on innovative approaches in head and neck oncology 2Health News:New clinical trial to determine ovarian cancer risks in African-American women 2Health News:Repeat MRI screening for breast cancer results in fewer false positives 2Health News:Survival After Stroke Better for Blacks 2Health News:Survival After Stroke Better for Blacks 3
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: